Suppr超能文献

骨细胞在多发性骨髓瘤骨病中的作用。

Role of osteocytes in multiple myeloma bone disease.

作者信息

Delgado-Calle Jesus, Bellido Teresita, Roodman G David

机构信息

aDepartment of Anatomy and Cell Biology bDivision of Endocrinology, Department of Medicine cDivision of Hematology/Oncology, Department of Medicine, Indiana University School of Medicine dRoudebush Veterans Administration Medical Center, Indianapolis, Indiana, USA.

出版信息

Curr Opin Support Palliat Care. 2014 Dec;8(4):407-13. doi: 10.1097/SPC.0000000000000090.

Abstract

PURPOSE OF REVIEW

Despite the increased knowledge of osteocyte biology, the contribution of this most abundant bone cell to the development and progression of multiple myeloma in bone is practically unexplored.

RECENT FINDINGS

Multiple myeloma bone disease is characterized by exacerbated bone resorption and the presence of osteolytic lesions that do not heal because of a concomitant reduction in bone formation. Osteocytes produce molecules that regulate both bone formation and resorption. Recent findings suggest that the life span of osteocytes is compromised in multiple myeloma patients with bone lesions. In addition, multiple myeloma cells affect the transcriptional profile of osteocytes by upregulating the production of pro-osteoclastogenic cytokines, stimulating osteoclast formation and activity. Further, patients with active multiple myeloma have elevated circulating levels of sclerostin, a potent inhibitor of bone formation which is specifically expressed by osteocytes in bone.

SUMMARY

Understanding the contribution of osteocytes to the mechanisms underlying the skeletal consequences of multiple myeloma bone disease has the potential to provide important new therapeutic strategies that specifically target multiple myeloma-osteocyte interactions.

摘要

综述目的

尽管对骨细胞生物学的认识有所增加,但这种最丰富的骨细胞对骨中多发性骨髓瘤的发生和发展的作用实际上尚未得到探索。

最新发现

多发性骨髓瘤骨病的特征是骨吸收加剧,且存在由于骨形成同时减少而无法愈合的溶骨性病变。骨细胞产生调节骨形成和吸收的分子。最近的发现表明,在患有骨病变的多发性骨髓瘤患者中,骨细胞的寿命受到损害。此外,多发性骨髓瘤细胞通过上调促破骨细胞生成细胞因子的产生来影响骨细胞的转录谱,刺激破骨细胞的形成和活性。此外,活动性多发性骨髓瘤患者循环中硬化蛋白水平升高,硬化蛋白是一种由骨中的骨细胞特异性表达的强效骨形成抑制剂。

总结

了解骨细胞对多发性骨髓瘤骨病骨骼后果潜在机制的作用,有可能提供针对多发性骨髓瘤-骨细胞相互作用的重要新治疗策略。

相似文献

1
Role of osteocytes in multiple myeloma bone disease.
Curr Opin Support Palliat Care. 2014 Dec;8(4):407-13. doi: 10.1097/SPC.0000000000000090.
2
Osteocyte-Related Cytokines Regulate Osteoclast Formation and Bone Resorption.
Int J Mol Sci. 2020 Jul 21;21(14):5169. doi: 10.3390/ijms21145169.
3
Osteocyte CIITA aggravates osteolytic bone lesions in myeloma.
Nat Commun. 2022 Jun 27;13(1):3684. doi: 10.1038/s41467-022-31356-7.
4
Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy.
Front Immunol. 2018 Oct 24;9:2467. doi: 10.3389/fimmu.2018.02467. eCollection 2018.
6
Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation.
Leukemia. 2012 Jun;26(6):1391-401. doi: 10.1038/leu.2011.381. Epub 2012 Jan 6.
7
[Mechanisms of myeloma-induced bone disease].
Clin Calcium. 2016 May;26(5):699-706.
8
Osteocyte control of osteoclastogenesis.
Bone. 2013 Jun;54(2):258-63. doi: 10.1016/j.bone.2012.08.121. Epub 2012 Aug 23.
9
Scl-Ab reverts pro-osteoclastogenic signalling and resorption in estrogen deficient osteocytes.
BMC Mol Cell Biol. 2020 Nov 4;21(1):78. doi: 10.1186/s12860-020-00322-w.

引用本文的文献

1
Mechanistic insights into bone destruction in multiple myeloma: Cellular and molecular perspectives.
J Bone Oncol. 2025 Mar 4;51:100668. doi: 10.1016/j.jbo.2025.100668. eCollection 2025 Apr.
2
Advancements in microenvironment-based therapies: transforming the landscape of multiple myeloma treatment.
Front Oncol. 2024 Jul 17;14:1413494. doi: 10.3389/fonc.2024.1413494. eCollection 2024.
3
Novel Developments in the Treatment of Multiple Myeloma-Associated Bone Disease.
Cancers (Basel). 2023 Nov 25;15(23):5585. doi: 10.3390/cancers15235585.
4
Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents.
J Bone Miner Metab. 2023 May;41(3):388-403. doi: 10.1007/s00774-023-01403-4. Epub 2023 Mar 1.
5
6
Osteocyte CIITA aggravates osteolytic bone lesions in myeloma.
Nat Commun. 2022 Jun 27;13(1):3684. doi: 10.1038/s41467-022-31356-7.
7
Sclerostin: From Molecule to Clinical Biomarker.
Int J Mol Sci. 2022 Apr 26;23(9):4751. doi: 10.3390/ijms23094751.
8
Management of lytic bone disease in lymphoplasmacytic lymphoma: A case report and review of the literature.
Clin Case Rep. 2021 Dec 7;9(12):e05181. doi: 10.1002/ccr3.5181. eCollection 2021 Dec.
9
Circulating cytokines present in multiple myeloma patients inhibit the osteoblastic differentiation of adipose stem cells.
Leukemia. 2022 Feb;36(2):540-548. doi: 10.1038/s41375-021-01428-6. Epub 2021 Sep 23.
10
The osteocyte as a signaling cell.
Physiol Rev. 2022 Jan 1;102(1):379-410. doi: 10.1152/physrev.00043.2020. Epub 2021 Aug 2.

本文引用的文献

3
Apoptotic osteocytes and the control of targeted bone resorption.
Curr Osteoporos Rep. 2014 Mar;12(1):121-6. doi: 10.1007/s11914-014-0194-3.
5
Osteogenic inhibition in multiple myeloma.
Cell J. 2013 Fall;15(3):266-71. Epub 2013 Aug 24.
6
Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma.
Leukemia. 2014 Feb;28(2):398-403. doi: 10.1038/leu.2013.258. Epub 2013 Sep 5.
7
Osteocyte-driven bone remodeling.
Calcif Tissue Int. 2014 Jan;94(1):25-34. doi: 10.1007/s00223-013-9774-y. Epub 2013 Sep 4.
8
RANKL expression, function, and therapeutic targeting in multiple myeloma and chronic lymphocytic leukemia.
Cancer Res. 2013 Jan 15;73(2):683-94. doi: 10.1158/0008-5472.CAN-12-2280. Epub 2012 Nov 8.
9
Osteocyte control of osteoclastogenesis.
Bone. 2013 Jun;54(2):258-63. doi: 10.1016/j.bone.2012.08.121. Epub 2012 Aug 23.
10
Myeloma cells suppress osteoblasts through sclerostin secretion.
Blood Cancer J. 2011 Jun;1(6):e27. doi: 10.1038/bcj.2011.22. Epub 2011 Jun 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验